Clinical experience with cinacalcet HCl

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 5, 2004, Pages

  Ureña Torres, Pablo ^a  

^a Clinique de l'Orangerie Aubervilliers   (France)

Author keywords

Calcimimetic therapy; Cinacalcet; Clinical trials; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D DERIVATIVE;

ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME REPRESSION; EXPERIENCE; HEMODIALYSIS PATIENT; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; IONIZATION; KIDNEY FAILURE; METABOLIC DISORDER; MINERAL METABOLISM; MORTALITY; MULTIPLE DRUG DOSE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; SOFT TISSUE CALCIFICATION; VOMITING;

ALKALINE PHOSPHATASE; CLINICAL TRIALS, PHASE III; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID GLANDS; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS;

EID: 4544339720     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1053     Document Type: Article

References (17)

1. Locatelli F, Cannata-Andía JB, Hörl WH, Fouque D, Heimburger O, Ritz E. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002: 17: 723-731
2. Nemeth EF. Pharmacological regulation of parathyroid hormone. Curr Pharm Des 2002; 8: 2077-2087
3. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
4. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
5. Kaye M. Hungry bone syndrome after surgical parathyroidectomy. Am J Kidney Dis 1997; 30: 730-731
6. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphate in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254
7. Drüeke TB, Cunningham J, Goodman WG et al. Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073 [abstract A3992. J Am Soc Nephrol 2001; 12: 764A
8. Cunningham J, Holzer H, Reichel H et al. on behalf of the AMG 073 study groups. IV Simposio Avances en Osteodistrofia Renal, Oviedo, June 6-7, 2002
9. Block GA, Coyne DW, Goodman WG et al. The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism (SHPT) [abstract SU-P0509]. J Am Soc Nephrol 2002; 13: 572A
10. de Francisco ALM, Suranyi M, Cunningham J et al. Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism: results of a European/Australian phase 3 study [abstract SA-PO742]. J Am Soc Nephrol 2003; 14: 461A
11. Block GA, Martin KJ, Turner SA et al. Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism [abstract SA-PO743]. J Am Soc Nephrol 2003; 14: 461A
12. Lindberg JS, Culleton B, Wong G et al. Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism [abstract SA-PO752]. J Am Soc Nephrol 2003; 14: 463A
13. Moe SM, Sprague SM, Adler S et al. Two-year treatment with the calcimimetic AMG 073 in hemodialysis patients with secondary hyperparathyroidism [abstract SU-P0508]. J Am Soc Nephrol 2002: 13: 572A
14. Goodman WG, Fadda GZ, Finkelstein FO et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract SA-PO741]. J Am Soc Nephrol 2003; 14: 460A
15. Coyne DW, Stegman MH, Azad H et al. Cinacalcet HCl controls secondary hyperparathyroidism regardless of gender, race, age, and geography in patients with chronic kidney disease receiving dialysis [abstract SA-PO754]. J Am Soc Nephrol 2003; 14: 464A
16. Quarles LD, Zeig S, Spiegel DM et al. Cinacalcet HCl (AMG 073) controls secondary hyperparathyroidism in dialysis patients regardless of disease severity [abstract SA-PO751]. J Am Soc Nephrol 2003; 14: 463A
17. Harris R, Padhi D, Salfi M et al. Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCl up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD) [abstract SA-PO746]. J Am Soc Nephrol 2003; 14: 462A